Bausch Health Companies (BHC) Earnings Date & Reports

Key Takeaways

• Bausch Health reported third quarter 2026 adjusted earnings per share (EPS) of $1.77, comfortably ahead of the consensus estimate near $1.27.
• Consolidated revenue reached $2.94 billion, above the roughly $2.75 billion estimate and up 10% from $2.68 billion a year earlier.
• Management raised full-year 2026 revenue and adjusted EBITDA guidance, reflecting stronger momentum across the portfolio.
• The company marked its fourteenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth.
• Quarterly adjusted EBITDA excluding Bausch + Lomb surpassed $1 billion for the first time, supporting more than $500 million of net debt reduction.
• Shares jumped roughly 12.5% in after-hours trading following the release.
• For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Discover how AI-driven tools can support your research by exploring Trending AI Robots.

Earnings Context and Why It Matters

Bausch Health Companies Inc. (NYSE: BHC) enters this report as a diversified global pharmaceutical company reporting across two primary segments: Bausch Health (which includes Salix, International, Solta Medical, and Diversified Products) and the separately tracked Bausch + Lomb eye care business. The third quarter 2026 results matter because they test whether the company can sustain the multi-year streak of revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) growth that has anchored its recovery story, while also demonstrating progress on a heavy debt load. With management repeatedly raising full-year guidance in prior quarters, investors are watching whether operational execution, pricing, and cash generation remain strong enough to support continued deleveraging and an improving financial profile.

Reported Results

Bausch Health posted adjusted EPS of $1.77, beating the consensus estimate of roughly $1.27 by about $0.50. Consolidated revenue of $2.94 billion topped the approximately $2.75 billion estimate and increased 10% from $2.68 billion in the prior-year period.

Segment performance was broad-based. The Salix division led with revenue of $831 million, up 16% from $716 million, driven primarily by Xifaxan, which grew 16%. The Bausch + Lomb segment generated $1.38 billion in revenue, up 7% from $1.28 billion a year earlier. Consolidated adjusted EBITDA attributable to Bausch Health reached $1.305 billion, up 32% from $986 million in the year-ago quarter.

Cash generation strengthened meaningfully, with operating cash flow of $813 million, more than double the $405 million produced in the third quarter of 2025. Management raised full-year 2026 revenue guidance to a range of $10.975 billion to $11.175 billion and increased adjusted EBITDA guidance to $4.315 billion to $4.415 billion, implying projected growth of 12% to 14%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters, including industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like BHC, the AI Screener offers a structured way to monitor developing setups across the market and refine a watchlist in less time.

Market Reaction and Investor Sentiment

The market responded positively to the results, with BHC shares surging roughly 12.5% in after-hours trading following the announcement. The reaction was driven by a combination of factors: a clear beat on both the top and bottom lines, a milestone in adjusted EBITDA excluding Bausch + Lomb crossing $1 billion, and a second guidance raise that lifted the full-year outlook above consensus. Investor sentiment was further supported by the company's improved cash generation and the more than $500 million reduction in net debt, which directly addresses a long-standing concern around the balance sheet. The strong after-hours move suggests the market viewed the quarter as validating management's execution strategy rather than a one-off result.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Bausch Health can sustain the operating momentum reflected in its raised guidance. The updated full-year targets imply continued mid-to-high single-digit revenue growth and low-double-digit adjusted EBITDA expansion, so execution across the Salix and Bausch + Lomb segments will remain central to the narrative.

One key factor to monitor is Xifaxan, which has been the primary growth engine within Salix. Pricing dynamics, prescription volume, and competitive or regulatory developments around the product could materially influence results in coming quarters. Investors should also watch the International and Solta Medical divisions, which face currency and demand variables that can introduce volatility.

Balance sheet progress will remain a focal point. The company's ability to continue reducing net debt, supported by strong operating cash flow, is critical to improving its financial flexibility and credit profile. Finally, attention will turn to any updates on segment-level strategy, including Bausch + Lomb, as management continues to evaluate pathways for long-term value creation. As always, these are considerations to monitor rather than signals for any specific action.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations